Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.83 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | GLA | P06280 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085418 | 0.91 | PDE5A (1.00) | PDE5AABCG2ALDH1A1CYP1A2GLA | |
| SCHEMBL27721053 | 0.91 | PDE5A (0.68) | PDE5AABCG2ALDH1A1CYP1A2GLA | |
| SCHEMBL27721055 | 0.85 | PDE5A (0.76) | PDE5AABCG2ALDH1A1CYP1A2GLA | |
| SCHEMBL22201623 | 0.83 | ABCG2 (0.86) | PDE5AABCG2ALDH1A1CYP1A2GLA | |
| SCHEMBL3121177 | 0.82 | EGFR (0.68) | PDE5AABCG2 | |
| SCHEMBL1063633 | 0.82 | PDE5A (0.56) | PDE5AABCG2ALDH1A1CYP1A2GLA | |
| SCHEMBL3113356 | 0.82 | PDE5A (0.76) | PDE5AABCG2ALDH1A1CYP1A2GLA | |
| SCHEMBL1083866 | 0.81 | CYP2D6 (0.81) | PDE5AABCG2ALDH1A1CYP1A2GLA | |
| SCHEMBL23577267 | 0.81 | EGFR (0.68) | PDE5AABCG2GBA1 | |
| SCHEMBL30013655 | 0.81 | EGFR (0.68) | PDE5AABCG2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345045-B2 | Pyrido-pyrimidine compounds as medicaments | SCIOS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| CN-101102787-A | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA INC (US) | 2008-01-09 | — | — | CN | disclosed |
| EP-1107959-B1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050220784-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-6903096-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-6277989-B1 | USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS | SCIOS, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6184226-B1 | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS | SCIOS INC. | 2001-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171123-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | PDE5A 1211/4885ABCG2 1096/4885ALDH1A1 3794/4885 |
| US-20050220784-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | PDE5A 1211/4885ABCG2 1096/4885ALDH1A1 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.